Pablo Pergola, MD
Enriched profileResearch director of the Clinical Advancement Center, PLLC, and member of Renal Associates PA · Clinical Advancement Center
Pablo Pergola is Research director of the Clinical Advancement Center, PLLC, and member of Renal Associates PA at Clinical Advancement Center. OpenAlex indexes 231 publications with 11,887 citations (h-index 55); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Nephrology profiles in the findmyKOL directory.
Data verified 14 Oct 2026
Overview
Updated 14 Oct 2026
Pablo Pergola, MD, is Research director of the Clinical Advancement Center, PLLC, and member of Renal Associates PA. The public record shows 231 publications with 11,887 citations (h-index 55), centered on Dialysis and Renal Disease Management, Chronic Kidney Disease and Diabetes, Erythropoietin and Anemia Treatment. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 28 companies.
- Most recent indexed publication: 2024 · Clinical pharmacology and therapeutics
- Top research focus: Dialysis and Renal Disease Management
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 108.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
Sponsor: ZyVersa Therapeutics, Inc.
- Safety Study of GCS-100 to Treat Chronic Kidney Disease
Sponsor: La Jolla Pharmaceutical Company
Industry payments
Updated 14 Oct 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20256 payments
- CSL BehringProgram year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year202520 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
52.7%Angiotensin receptor blocker (ARB)9.6%Candesartan Cilexetil55%Losartan Potassium31%Valsartan15%Part D<11 patientsBeta blocker7.1%Carvedilol31%Bisoprolol Fumarate30%Metoprolol Succinate24%Metoprolol Tartrate15%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
35.2%SGLT2 inhibitor21.5%Jardiance64%Farxiga32%Invokana4%Part D<11 patientsGLP-1 receptor agonist8.6%Trulicity58%Ozempic42%Part D≥16 patients+ 5 more classes in this area
Musculoskeletal
6%Xanthine oxidase inhibitor6%Allopurinol100%Part D≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
2 congress contributions (2014–2023) across ASCO, ASH per OpenAlex. The most recent:
- The evaluation of denosumab safety in patients with chronic kidney disease: An open-label study.
ASCO Annual Meeting
ASCO2014Co-authorOnline-only
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease.
Clinical pharmacology and therapeutics
Clinical Trial2024 - Phosphate Frustration: Treatment Options to Complement Current Therapies.
International journal of nephrology
Review2022
Most-cited works
by citation count (OpenAlex)- 01Bardoxolone Methyl and Kidney Function in CKD with Type 2 DiabetesArticle887 citations2011
- 02
- 03
- 04
- 05Sodium Zirconium Cyclosilicate in HyperkalemiaArticle506 citations2014
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD from Universidad del Salvador
School of Medicine, Buenos Aires, Argentina
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unicycive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unicycive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unicycive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cms.gov ↗
Secondary affiliations
appointments beyond the home institution- UT Health San Antonio
Department of Physiology (post-doctoral training)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unicycive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unicycive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)